Indivior Pharmaceuticals Inc Stock Price, News & Analysis

Indivior (Nasdaq: INDV) completed redomiciliation from the United Kingdom to the United States effective Jan 26, 2026. A new Delaware parent, Indivior Pharmaceuticals, Inc. (IPI), is now the parent and Indivior PLC was renamed Indivior Ltd. Shareholders received one IPI common share for each Indivior PLC ordinary share as of the scheme record date, and Indivior common stock remains listed on Nasdaq under INDV. IPI is now a U.S. domestic issuer subject to SEC reporting and Nasdaq exchange rules. The redomiciliation was approved at an extraordinary general meeting on Dec 11, 2025.

Indivior (Nasdaq: INDV) provided full-year 2026 financial guidance and a business update. Management expects total net revenue $1,125M–$1,195M, SUBLOCADE net revenue $905M–$945M, non-GAAP operating expenses $430M–$450M, and adjusted EBITDA $535M–$575M for 2026. The company expects SUBLOCADE net revenue growth of ~11% at the midpoint and a ~35% increase in adjusted EBITDA with a 14 percentage-point expansion in adjusted EBITDA margin at the midpoint.

Recent items: completed Phase I of a restructuring program with expected annual non-GAAP OPEX savings of at least $150M, entered Phase II to accelerate dispense-unit growth, gained inclusion in the S&P SmallCap 600, received shareholder approval to re-domicile to the U.S. effective Jan 26, 2026, and paid $295M to conclude a legacy DOJ matter.

Indivior (Nasdaq: INDV) announced it was added to the S&P SmallCap 600 index, effective December 22, 2025. The company said the inclusion aligns its capital markets presence with a sharpened U.S. business profile and supports growth of SUBLOCADE, its first‑in‑class long‑acting injectable for moderate to severe opioid use disorder.

The S&P SmallCap 600 tracks 600 U.S. small‑cap companies with market capitalizations generally between $1.2 billion and $8.0 billion and applies liquidity and viability criteria for inclusion.

Indivior (Nasdaq: INDV) reported results from a randomized, double-blind trial showing monthly SUBLOCADE extended-release buprenorphine at both 100 mg and 300 mg produced rapid, clinically meaningful reductions in opioid use and improved abstinence in people with moderate-to-severe opioid use disorder.

Participants reduced opioid use from >43 instances/week at screening to <3 instances/week by week 3, a decline maintained through week 38. Post-hoc analyses found the 300-mg maintenance dose achieved significantly higher abstinence in participants with high-frequency fentanyl use. Both doses were well tolerated with no new safety signals; injection-site reactions were more common with 300 mg but were mild-to-moderate and not linked to discontinuation. The post-hoc findings were exploratory and not pre-specified.

Indivior (Nasdaq: INDV) announced on November 20, 2025 that it has concluded a legacy U.S. Department of Justice matter by paying in full the outstanding obligation of $295 million. With receipt of the payment by the DOJ, the resolution agreement will be terminated.

The company said the payment was funded with cash on hand, and management described the milestone as removing a significant liability and simplifying the company's capital structure while reaffirming its compliance commitments.

Indivior (NASDAQ: INDV) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2, 2025. Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick will host 1x1 and group meetings and will join a fireside discussion at 3:30 p.m. ET on the same day. Interested investors should contact their Piper Sandler representative to schedule meetings. The fireside discussion will be publicly available via the Piper Sandler Fireside Chat Live Webcast.

Indivior (Nasdaq: INDV) presented three real-world evidence posters at AMCP Nexus 2025 on Nov 3, 2025 showing clinical and economic benefits of monthly injectable buprenorphine SUBLOCADE for opioid use disorder.

Key findings: lower relapse and recurrence rates, reduced emergency and inpatient use, and substantially lower medical costs in high-adherence patients across Medicaid and commercial cohorts (example: total medical costs ~$23,051 vs $43,357). Analyses also reported lower infectious complications (skin infections -37%, bacteremia -62%) versus transmucosal buprenorphine. Limitations include retrospective claims/EHR design, lack of baseline adjustments, and overlap with the COVID-19 period.

Indivior (NASDAQ: INDV) reported Q3 2025 results and raised full-year guidance on Oct 30, 2025. Total net revenue was $314m in Q3 (+2% YoY) and SUBLOCADE net revenue was $219m (+15% YoY). The company raised FY2025 revenue guidance to $1.18–1.22bn and adjusted EBITDA to $400–420m. Management expects at least $150m of annual operating expense savings beginning 2026 after organizational simplification and ROW optimization. Q3 non-GAAP gross margin was 84% and adjusted EBITDA was $120m. Actions include ROW market exits, discontinuing OPVEE commercial support, and an intended U.S. redomicile.

Indivior (NASDAQ: INDV) will participate in the Stifel 2025 Healthcare Conference in New York City.

Chief Executive Officer Joe Ciaffoni and Chief Financial Officer Ryan Preblick will host 1x1 and group meetings and will appear in a public fireside discussion on Thursday, November 13, 2025 at 8:40 a.m. U.S. EST. Interested investors should contact their Stifel representative to schedule meetings. The fireside discussion will be available via a public webcast.